295 related articles for article (PubMed ID: 25145672)
1. SAR405838: an optimized inhibitor of MDM2-p53 interaction that induces complete and durable tumor regression.
Wang S; Sun W; Zhao Y; McEachern D; Meaux I; Barrière C; Stuckey JA; Meagher JL; Bai L; Liu L; Hoffman-Luca CG; Lu J; Shangary S; Yu S; Bernard D; Aguilar A; Dos-Santos O; Besret L; Guerif S; Pannier P; Gorge-Bernat D; Debussche L
Cancer Res; 2014 Oct; 74(20):5855-65. PubMed ID: 25145672
[TBL] [Abstract][Full Text] [Related]
2. SAR405838: A Novel and Potent Inhibitor of the MDM2:p53 Axis for the Treatment of Dedifferentiated Liposarcoma.
Bill KL; Garnett J; Meaux I; Ma X; Creighton CJ; Bolshakov S; Barriere C; Debussche L; Lazar AJ; Prudner BC; Casadei L; Braggio D; Lopez G; Zewdu A; Bid H; Lev D; Pollock RE
Clin Cancer Res; 2016 Mar; 22(5):1150-60. PubMed ID: 26475335
[TBL] [Abstract][Full Text] [Related]
3. Molecular hybridization design and synthesis of novel spirooxindole-based MDM2 inhibitors endowed with BCL2 signaling attenuation; a step towards the next generation p53 activators.
Lotfy G; Abdel Aziz YM; Said MM; El Ashry ESH; El Tamany ESH; Abu-Serie MM; Teleb M; Dömling A; Barakat A
Bioorg Chem; 2021 Dec; 117():105427. PubMed ID: 34794098
[TBL] [Abstract][Full Text] [Related]
4. Identification of a new class of MDM2 inhibitor that inhibits growth of orthotopic pancreatic tumors in mice.
Wang W; Qin JJ; Voruganti S; Wang MH; Sharma H; Patil S; Zhou J; Wang H; Mukhopadhyay D; Buolamwini JK; Zhang R
Gastroenterology; 2014 Oct; 147(4):893-902.e2. PubMed ID: 25016295
[TBL] [Abstract][Full Text] [Related]
5. BI-907828, a novel potent MDM2 inhibitor, inhibits glioblastoma brain tumor stem cells in vitro and prolongs survival in orthotopic xenograft mouse models.
Hao X; Bahia RK; Cseh O; Bozek DA; Blake S; Rinnenthal J; Weyer-Czernilofsky U; Rudolph D; Artee Luchman H
Neuro Oncol; 2023 May; 25(5):913-926. PubMed ID: 36521007
[TBL] [Abstract][Full Text] [Related]
6. Discovery of JN122, a Spiroindoline-Containing Molecule that Inhibits MDM2/p53 Protein-Protein Interaction and Exerts Robust In Vivo Antitumor Efficacy.
Cheng J; Yan Z; Jiang K; Liu C; Xu D; Lyu X; Hu X; Zhang S; Zhou Y; Li J; Zhao Y
J Med Chem; 2023 Dec; 66(24):16991-17025. PubMed ID: 38062557
[TBL] [Abstract][Full Text] [Related]
7. A novel small molecule inhibitor of MDM2-p53 (APG-115) enhances radiosensitivity of gastric adenocarcinoma.
Yi H; Yan X; Luo Q; Yuan L; Li B; Pan W; Zhang L; Chen H; Wang J; Zhang Y; Zhai Y; Qiu MZ; Yang DJ
J Exp Clin Cancer Res; 2018 May; 37(1):97. PubMed ID: 29716622
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and biological evaluation of 4-imidazolidinone-containing compounds as potent inhibitors of the MDM2/p53 interaction.
Lin Z; Liu C; Yan Z; Cheng J; Wang X; Zhou F; Lyu X; Zhang S; Zhang D; Meng X; Zhao Y
Eur J Med Chem; 2024 Apr; 270():116366. PubMed ID: 38581730
[TBL] [Abstract][Full Text] [Related]
9. Novel isatin-derived molecules activate p53 via interference with Mdm2 to promote apoptosis.
Fedorova O; Daks A; Petrova V; Petukhov A; Lezina L; Shuvalov O; Davidovich P; Kriger D; Lomert E; Tentler D; Kartsev V; Uyanik B; Tribulovich V; Demidov O; Melino G; Barlev NA
Cell Cycle; 2018; 17(15):1917-1930. PubMed ID: 30109812
[TBL] [Abstract][Full Text] [Related]
10. Targeting MDM2 enhances antileukemia immunity after allogeneic transplantation via MHC-II and TRAIL-R1/2 upregulation.
Ho JNHG; Schmidt D; Lowinus T; Ryoo J; Dopfer EP; Gonzalo Núñez N; Costa-Pereira S; Toffalori C; Punta M; Fetsch V; Wertheimer T; Rittmann MC; Braun LM; Follo M; Briere C; Vinnakota JM; Langenbach M; Koppers F; Shoumariyeh K; Engel H; Rückert T; Märklin M; Holzmayer S; Illert AL; Magon F; Andrieux G; Duquesne S; Pfeifer D; Staniek J; Rizzi M; Miething C; Köhler N; Duyster J; Menssen HD; Boerries M; Buescher JM; Cabezas-Wallscheid N; Blazar BR; Apostolova P; Vago L; Pearce EL; Becher B; Zeiser R
Blood; 2022 Sep; 140(10):1167-1181. PubMed ID: 35853161
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic targeting of ARID1A-deficient cancer cells with RITA (Reactivating p53 and inducing tumor apoptosis).
Wang Z; Zhang X; Luo Y; Song Y; Xiang C; He Y; Wang K; Yu Y; Wang Z; Peng W; Ding Y; Liu S; Wu C
Cell Death Dis; 2024 May; 15(5):375. PubMed ID: 38811536
[TBL] [Abstract][Full Text] [Related]
12. mRNA display selection of an optimized MDM2-binding peptide that potently inhibits MDM2-p53 interaction.
Shiheido H; Takashima H; Doi N; Yanagawa H
PLoS One; 2011 Mar; 6(3):e17898. PubMed ID: 21423613
[TBL] [Abstract][Full Text] [Related]
13. Mdm2-P53 Interaction Inhibitor with Cisplatin Enhances Apoptosis in Colon and Prostate Cancer Cells In-Vitro.
Gupta A; Behl T; Heer HR; Deshmukh R; Sharma PL
Asian Pac J Cancer Prev; 2019 Nov; 20(11):3341-3351. PubMed ID: 31759358
[TBL] [Abstract][Full Text] [Related]
14. Initial Testing (Stage 1) of MK-8242-A Novel MDM2 Inhibitor-by the Pediatric Preclinical Testing Program.
Kang MH; Reynolds CP; Kolb EA; Gorlick R; Carol H; Lock R; Keir ST; Maris JM; Wu J; Lyalin D; Kurmasheva RT; Houghton PJ; Smith MA
Pediatr Blood Cancer; 2016 Oct; 63(10):1744-52. PubMed ID: 27238606
[TBL] [Abstract][Full Text] [Related]
15. Improving anticancer activity towards colon cancer cells with a new p53-activating agent.
Raimundo L; Espadinha M; Soares J; Loureiro JB; Alves MG; Santos MMM; Saraiva L
Br J Pharmacol; 2018 Oct; 175(20):3947-3962. PubMed ID: 30076608
[TBL] [Abstract][Full Text] [Related]
16. Designed novel nuclear localizing anticancer peptide targets p53 negative regulator MDM2 protein.
Mukherjee N; Bhunia D; Garai PK; Mondal P; Barman S; Ghosh S
J Pept Sci; 2024 Jan; 30(1):e3535. PubMed ID: 37580909
[TBL] [Abstract][Full Text] [Related]
17. The pyrido[b]indole MDM2 inhibitor SP-141 exerts potent therapeutic effects in breast cancer models.
Wang W; Qin JJ; Voruganti S; Srivenugopal KS; Nag S; Patil S; Sharma H; Wang MH; Wang H; Buolamwini JK; Zhang R
Nat Commun; 2014 Oct; 5():5086. PubMed ID: 25271708
[TBL] [Abstract][Full Text] [Related]
18. Small-molecule correctors and stabilizers to target p53.
Fallatah MMJ; Law FV; Chow WA; Kaiser P
Trends Pharmacol Sci; 2023 May; 44(5):274-289. PubMed ID: 36964053
[TBL] [Abstract][Full Text] [Related]
19. BAI1 Suppresses Medulloblastoma Formation by Protecting p53 from Mdm2-Mediated Degradation.
Zhu D; Osuka S; Zhang Z; Reichert ZR; Yang L; Kanemura Y; Jiang Y; You S; Zhang H; Devi NS; Bhattacharya D; Takano S; Gillespie GY; Macdonald T; Tan C; Nishikawa R; Nelson WG; Olson JJ; Van Meir EG
Cancer Cell; 2018 Jun; 33(6):1004-1016.e5. PubMed ID: 29894688
[TBL] [Abstract][Full Text] [Related]
20. Development of MDM2 degraders based on ligands derived from Ugi reactions: Lessons and discoveries.
Wang B; Liu J; Tandon I; Wu S; Teng P; Liao J; Tang W
Eur J Med Chem; 2021 Jul; 219():113425. PubMed ID: 33862513
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
